Suraksha Diagnostic Share Price Target 2026 Analyst Forecast Bull and Bear Case
- June 24, 2026
- Posted by: Kunal Singla
- Category: News
The Suraksha Diagnostic share price target 2026 is Rs 330, implying approximately 20 percent upside from the current market price of Rs 276.45 (NSE: SURAKSHA). With Q4 FY26 results released in 2026 and Diagnostic Laboratories and Pathology tailwinds in focus, the Rs 330 price objective is supported by the FY27 earnings recovery thesis.
Suraksha Diagnostic (NSE: SURAKSHA) is a Diagnostic Laboratories and Pathology company trading at Rs 276.45 with a market capitalisation of Rs 1,659 crore. Analysts have set the Suraksha Diagnostic share price target at Rs 330 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.
Click Here – Get Free Investment Predictions
Suraksha Diagnostic Share Price Target 2026: Key Takeaways
- Suraksha Diagnostic share price target 2026: Rs 330 (20% upside from CMP Rs 276.45)
- Bull case: Rs 400 | Bear case: Rs 220
- Ticker: SURAKSHA | Sector: Diagnostic Laboratories and Pathology | MCap: Rs 1,659 crore
- 52W range: Rs 192 to Rs 454 | PE: 30x
- Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
- Key risk: FY27 earnings miss or FII outflows from Indian equities
Suraksha Diagnostic Company Overview
Suraksha Diagnostic (NSE: SURAKSHA) is a Kolkata-based diagnostic laboratory chain operating 250-plus labs across West Bengal, Bihar, and Assam, listed in 2024 with FY26 revenue growing on volume expansion and B2B hospital channel development. At CMP Rs 276.45 against a 52 week range of Rs 192 to Rs 454, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 1,659 crore with trailing PE of 30x. Compared to peers in diagnostics like Metropolis Healthcare and Vijaya Diagnostics, Suraksha Diagnostic is positioned as a potential re-rating candidate toward the Rs 330 price objective on FY27 earnings delivery.
| Parameter | Value |
|---|---|
| NSE Ticker | SURAKSHA |
| Sector | Diagnostic Laboratories and Pathology |
| CMP (2026) | Rs 276.45 |
| 52 Week High | Rs 454 |
| 52 Week Low | Rs 192 |
| Market Cap | Rs 1,659 crore |
| Trailing PE | 30x |
| 12-Month Analyst Target | Rs 330 |
| Bull Case Target | Rs 400 |
| Bear Case Target | Rs 220 |
Why Is the Suraksha Diagnostic Share Price Target Set at Rs 330 for 2026
FY27 Earnings Recovery and Revenue Acceleration
The Suraksha Diagnostic share price target of Rs 330 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 276.45.
Structural Sector Tailwinds in Diagnostic Laboratories and Pathology
The Diagnostic Laboratories and Pathology sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Suraksha Diagnostic’s position among peers in diagnostics like Metropolis Healthcare and Vijaya Diagnostics creates a structural growth runway. Sustained outperformance is one of the key conditions for the Rs 400 bull case to materialise.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Suraksha Diagnostic’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 330 analyst consensus.
Union Budget 2026-27 Capex Push and Policy Support
Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Suraksha Diagnostic’s Diagnostic Laboratories and Pathology operations, improving the probability of achieving the Rs 330 price objective through FY27 earnings delivery.
FII Flow Normalisation After the 2026 Tariff Shock
As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 30x PE, Suraksha Diagnostic is positioned as a beneficiary of institutional reallocation toward the Rs 400 bull case over the medium term.
Suraksha Diagnostic Share Price Targets: Short Term, 12 Month, and Long Term
Short Term Suraksha Diagnostic Share Price Target
Near-term support for Suraksha Diagnostic is anchored close to the 52 week low of Rs 192. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 276.45.
12-Month Suraksha Diagnostic Share Price Target 2026
The 12-month Suraksha Diagnostic share price target 2026 is Rs 330, implying approximately 20 percent upside from CMP Rs 276.45. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.
Long Term Suraksha Diagnostic Share Price Target: FY27 to FY28
The long term Suraksha Diagnostic share price target for FY27 to FY28 is Rs 400 in the bull case, requiring full earnings delivery, re-rating among peers in diagnostics like Metropolis Healthcare and Vijaya Diagnostics, and sustained institutional buying over a 2 to 3 year horizon.
Bull Case and Bear Case Scenarios for Suraksha Diagnostic in 2026
Bull Case Suraksha Diagnostic Share Price Target: Rs 400
The bull case Suraksha Diagnostic share price target of Rs 400 materialises when FY27 earnings beat analyst estimates, Diagnostic Laboratories and Pathology tailwinds accelerate, and FII flows return strongly to Indian equities. From CMP Rs 276.45, this represents approximately 45 percent potential upside.
Bear Case Suraksha Diagnostic Share Price Target: Rs 220
The bear case Suraksha Diagnostic share price target of Rs 220 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 192.
| Scenario | Target | Key Conditions |
|---|---|---|
| Bull Case | Rs 400 | FY27 beat, sector re-rating, FII inflows |
| Base Case (Analyst Target) | Rs 330 | In-line FY27 delivery, partial FII recovery |
| Bear Case | Rs 220 | FY27 miss, guidance cut, FII outflows persist |
Key Risks That Could Derail the Suraksha Diagnostic 2026 Price Objective
Global Macro and US Tariff Headwinds
Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Suraksha Diagnostic share price target of Rs 330, with FII outflows being the direct transmission mechanism to Indian equity valuations.
FY27 Earnings Miss and Guidance Risk
An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 330 analyst price objective. Investors must monitor quarterly results and management commentary closely.
Competitive Intensity Among Diagnostic Laboratories and Pathology Peers
Intensifying competition from peers in diagnostics like Metropolis Healthcare and Vijaya Diagnostics could compress Suraksha Diagnostic’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 330 analyst target for 2026.
Liquidity Risk and FII Selling Pressure
Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.
How to Invest in Suraksha Diagnostic
Check the Univest Screener for live data
Before considering any investment based on the Suraksha Diagnostic share price target of Rs 330, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Diagnostic Laboratories and Pathology sector demand.
Open a Demat account with a SEBI registered stockbroker to trade Suraksha Diagnostic (NSE: SURAKSHA) with full regulatory protection. Study the competitive landscape among peers in diagnostics like Metropolis Healthcare and Vijaya Diagnostics before executing any position.
Plan your entry using the 52 week low of Rs 192 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 330 price objective. Always set a stop loss below the 52 week low.
Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.
Download the Univest iOS App or the Univest Android App to track Suraksha Diagnostic’s live share price and receive daily stock recommendations.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.
FAQs on Suraksha Diagnostic Share Price Target 2026
What is the Suraksha Diagnostic share price target for 2026?
Ans. The Suraksha Diagnostic share price target 2026 is Rs 330, implying approximately 20 percent upside from CMP Rs 276.45. Bull case is Rs 400, bear case is Rs 220.
What was the Suraksha Diagnostic share price target for 2025?
Ans. The 2025 price objective for Suraksha Diagnostic was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 330, reflecting FY27 growth potential from CMP Rs 276.45.
Is Suraksha Diagnostic a good investment at Rs 276.45?
Ans. At Rs 276.45, Suraksha Diagnostic offers potential upside toward Rs 330 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.
What are the key risks to the Suraksha Diagnostic share price target 2026?
Ans. Key risks to the Suraksha Diagnostic share price target of Rs 330 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Diagnostic Laboratories and Pathology. Monitoring quarterly results is essential.
What is the 52 week high and low of Suraksha Diagnostic?
Ans. The 52 week high of Suraksha Diagnostic is Rs 454 and the 52 week low is Rs 192. At CMP Rs 276.45, the stock offers potential upside toward the Rs 330 price objective.
What are the main growth catalysts for Suraksha Diagnostic in 2026?
Ans. Key catalysts include FY27 PAT recovery, Diagnostic Laboratories and Pathology tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.
How does Suraksha Diagnostic compare to its peers?
Ans. Suraksha Diagnostic operates in Diagnostic Laboratories and Pathology alongside peers in diagnostics like Metropolis Healthcare and Vijaya Diagnostics. At CMP Rs 276.45 with MCap Rs 1,659 crore, it is a potential re-rating candidate toward the Suraksha Diagnostic share price target of Rs 330 on FY27 delivery.
What is the Suraksha Diagnostic share price target for 2027?
Ans. The long-term Suraksha Diagnostic share price target for FY27 to FY28 is Rs 400 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.
